← All trials
NCT04456634
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 10, 2020
- Primary completion
- Nov 17, 2020
- Completion date
- Nov 17, 2020
- First posted
- Jul 2, 2020
- Last posted
- Nov 24, 2020
- Enrollment
- 8
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Medicines for Malaria VentureLead sponsor
- Nucleus Network LtdCollaborator
- Nucleus Network LtdOverall official - principal investigator
- Southern Star Research Pty Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.